121 related articles for article (PubMed ID: 2196627)
1. Clinical predictors of treatment response in obsessive compulsive disorder: exploratory analyses from multicenter trials of clomipramine.
DeVeaugh-Geiss J; Katz R; Landau P; Goodman W; Rasmussen S
Psychopharmacol Bull; 1990; 26(1):54-9. PubMed ID: 2196627
[TBL] [Abstract][Full Text] [Related]
2. Predictors of drug treatment response in obsessive-compulsive disorder.
Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G
J Clin Psychiatry; 1995 Aug; 56(8):368-73. PubMed ID: 7635854
[TBL] [Abstract][Full Text] [Related]
3. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ
J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
[TBL] [Abstract][Full Text] [Related]
4. Preliminary results from a multicenter trial of clomipramine in obsessive-compulsive disorder.
DeVeaugh-Geiss J; Landau P; Katz R
Psychopharmacol Bull; 1989; 25(1):36-40. PubMed ID: 2672070
[TBL] [Abstract][Full Text] [Related]
5. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder--a multicenter trial.
DeVeaugh-Geiss J; Moroz G; Biederman J; Cantwell D; Fontaine R; Greist JH; Reichler R; Katz R; Landau P
J Am Acad Child Adolesc Psychiatry; 1992 Jan; 31(1):45-9. PubMed ID: 1537780
[TBL] [Abstract][Full Text] [Related]
6. Predictors of treatment response in obsessive-compulsive disorder: multivariate analyses from a multicenter trial of clomipramine.
Ackerman DL; Greenland S; Bystritsky A; Morgenstern H; Katz RJ
J Clin Psychopharmacol; 1994 Aug; 14(4):247-54. PubMed ID: 7962680
[TBL] [Abstract][Full Text] [Related]
7. A predictive study of obsessive-compulsive disorder response to clomipramine.
Alarcon RD; Libb JW; Spitler D
J Clin Psychopharmacol; 1993 Jun; 13(3):210-3. PubMed ID: 8354737
[TBL] [Abstract][Full Text] [Related]
8. Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients.
Greist JH; Jefferson JW; Rosenfeld R; Gutzmann LD; March JS; Barklage NE
J Clin Psychiatry; 1990 Jul; 51(7):292-7. PubMed ID: 2195006
[TBL] [Abstract][Full Text] [Related]
9. [Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature].
Etain B; Bonnet-Perrin E
Encephale; 2001; 27(3):280-9. PubMed ID: 11488259
[TBL] [Abstract][Full Text] [Related]
10. Symptoms and physiologic manifestations in obsessive compulsive patients before and after treatment with clomipramine.
Hoehn-Saric R; McLeod DR; Zimmerli WD; Hipsley PA
J Clin Psychiatry; 1993 Jul; 54(7):272-6. PubMed ID: 8335655
[TBL] [Abstract][Full Text] [Related]
11. A clomipramine dosage reduction study in the course of long-term treatment of obsessive-compulsive disorder patients.
Pato MT; Hill JL; Murphy DL
Psychopharmacol Bull; 1990; 26(2):211-4. PubMed ID: 2236458
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy of obsessive-compulsive disorder.
Klein DF
Encephale; 1990; 16 Spec No():331-4. PubMed ID: 2209491
[TBL] [Abstract][Full Text] [Related]
13. Clinical features associated with treatment response in obsessive-compulsive disorder.
Shavitt RG; Belotto C; Curi M; Hounie AG; Rosário-Campos MC; Diniz JB; Ferrão YA; Pato MT; Miguel EC
Compr Psychiatry; 2006; 47(4):276-81. PubMed ID: 16769302
[TBL] [Abstract][Full Text] [Related]
14. [Prospective follow-up over a 12 month period of a cohort of 155 patients with obsessive-compulsive disorder: phase III National DRT-TOC Study].
Hantouche EG; Bouhassira M; Lancrenon S
Encephale; 2000; 26(6):73-83. PubMed ID: 11217541
[TBL] [Abstract][Full Text] [Related]
15. Six-year follow-up after exposure and clomipramine therapy for obsessive compulsive disorder.
O'Sullivan G; Noshirvani H; Marks I; Monteiro W; Lelliott P
J Clin Psychiatry; 1991 Apr; 52(4):150-5. PubMed ID: 2016246
[TBL] [Abstract][Full Text] [Related]
16. The Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS): an instrument for assessing obsessive-compulsive symptom dimensions.
Rosario-Campos MC; Miguel EC; Quatrano S; Chacon P; Ferrao Y; Findley D; Katsovich L; Scahill L; King RA; Woody SR; Tolin D; Hollander E; Kano Y; Leckman JF
Mol Psychiatry; 2006 May; 11(5):495-504. PubMed ID: 16432526
[TBL] [Abstract][Full Text] [Related]
17. [Hungarian translation of the Dimensional Yale-Brown Obsessive-Compulsive Scale and our first experiences with the test].
Harsányi A; Csigó K; Demeter G; Rajnai C; Németh A; Racsmány M
Psychiatr Hung; 2009; 24(1):18-59. PubMed ID: 19542567
[TBL] [Abstract][Full Text] [Related]
18. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder.
Chouinard G; Goodman W; Greist J; Jenike M; Rasmussen S; White K; Hackett E; Gaffney M; Bick PA
Psychopharmacol Bull; 1990; 26(3):279-84. PubMed ID: 2274626
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy assessment of fluoxetine treatment of outpatients with obsessive-compulsive disorder: a preliminary report].
Wandzel L
Psychiatr Pol; 1997; 31(4):429-35. PubMed ID: 9527686
[TBL] [Abstract][Full Text] [Related]
20. High-dose escitalopram for the treatment of obsessive-compulsive disorder.
Rabinowitz I; Baruch Y; Barak Y
Int Clin Psychopharmacol; 2008 Jan; 23(1):49-53. PubMed ID: 18090508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
